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The National Cancer Institute (NCI) clinical cooperative groups have been instrumental over
the past 50 years in developing clinical trials and evidence-based clinical trial processes
for improvements in patient care. The cooperative groups are undergoing a transformation
process to launch, conduct, and publish clinical trials more rapidly. Institutional participation
in clinical trials can be made more efﬁcient and include the expansion of relationships with
international partners. This paper reviews the current processes that are in use in radiation
therapy trials and the importance of maintaining effective credentialing strategies to assure
the quality of the outcomes of clinical trials. The paper offers strategies to streamline
and harmonize credentialing tools and processes moving forward as the NCI undergoes
transformative change in the conduct of clinical trials.
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INTRODUCTION
The national cooperative group clinical trials system is more than
50 years old. In the beginning the newly established cooperative
groups placed emphasis on clinical trials involving leukemia and
lymphoma. As these trials matured and acquired the conﬁdence
and enthusiasm of the clinical oncology community, clinical tri-
als in epithelial oncology began to mature. Accordingly, radiation
therapy became incorporated as an important discipline in the
clinical cooperative group community. In 1968, the Committee for
Radiation Studies recognized the need for consistency in the deliv-
ered radiation dose to the patient. The committee was made aware
of signiﬁcant variations in computation algorithms used to calcu-
late radiation dose as well as signiﬁcant variability in the delivery
of daily radiation treatment. In 1969, the Radiologic Physics Cen-
ter (RPC) was funded by the National Cancer Institute (NCI) with
themission to assure both the NCI and clinical cooperative system
that institutions participating in the clinical trials process deliver
comparable and consistent radiation therapy compliant to study
objectives. Herring and Compton (1970) published an analysis
on patients treated for laryngeal carcinoma in 1970 indicating
that radiation therapy had to be delivered to a speciﬁc radiation
dose and volume within 5% of the intent of treatment in order
to achieve optimal clinical outcome, a paradigm that remains as
important today as it was in 1970. In early clinical trials there
was considerable variability identiﬁed in both radiation dose and
volume of treatment with many major deviations identiﬁed on
multiple studies (Table 1) making interpretation of the study dif-
ﬁcult to assess. To further complicate matters, there was no clear
mechanism inplace to acquire and reviewprotocol data in a central
location, making analysis limited and incomplete. It was challeng-
ing to use these studies as a vehicle to identify a standard of care.
The Quality Assurance Review Center (QARC) was established
in 1976 as a subset of the radiation therapy committee of the
Cancer and Leukemia Group B (CALGB) with a responsibility to
acquire radiation therapy protocol information, review data with
responsible clinical trial investigators, and provide institutional
feedback on protocol performance. The ofﬁce offered similar ser-
vice for the National Wilms Tumor Study Group (NWTSG) and
the Intergroup Rhabdomyosarcoma Study Group (IRSG). QARC
became independently funded through Cancer Therapy Evalua-
tion Program (CTEP) in 1980 when the pediatric divisions of both
CALGB and Southwest Oncology Group (SWOG) separated from
the adult Cooperative Groups and formed the Pediatric Oncology
Group (POG). QARC and RPC have been continuously funded
to date with quality assurance service portfolio evolving as clin-
ical protocols have matured (FitzGerald et al., 2008; Ibbott et al.,
2008). The Radiation Therapy Oncology Group (RTOG) devel-
oped an internal mechanism for quality assurance as part of the
primary program. The image-guided therapy center (ITC) was
developed to work in collaboration with the RTOG initially as
the resource for three-dimensional planning and has worked in
close collaboration with the RTOG since that time point (Eis-
bruch et al., 2010). All four organizations are housed under the
general umbrella of the Advanced Technology Consortium (ATC)
designed to establish transparent guidelines and standards in radi-
ation oncology throughout all of the cooperative groups. By 2014,
all radiation therapy anddiagnostic imagingquality assurance cen-
ters will be integrated as a single entity called the Imaging and
Radiation Oncology Core (IROC) as part of the re-organization
of the clinical trial effort managed by the NCI.
Review of data from studies for protocol quality assurance
management initially was solely performed in a retrospective
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Table 1 | Comparison of deviation rates for clinical trial studies with and without radiotherapy credentialing.
Clinical trial group Disease site Credentialing Major deviations Minor deviations Number of patients
GOG Endometrial No 29 (15%) 37 (19%) 197
NSABP Breast No 135 (9%) 214 (15%) 1460
RTOG Cervical No 43 (14%) 76 (24%) 315
RTOG H&N No 75 (7%) 188 (18%) 1073
GOG Cervical (LDR) No 57 (21%) 87 (32%) 275
GOG Cervical (HDR) Yes 0 15 (21%) 70
COMS Ocular Yes 43 (5%) 47 (4%) 1166
RTOG Breast Yes 0 4 (4%) 100
RTOG Prostate Yes 0 6 (5%) 117
NSABP Breast Yes 3 (0.3%) 172 (11%) 1612
manner well past completion of the study. As a result, devia-
tion rates on study were (and often remain) unacceptably high
and only captured in retrospect. The approach and concept devel-
opment for quality assurance had to be re-engineered to address
the issues surrounding both computational and volumetric devi-
ations on study (FitzGerald, 2012). In 1985, the Collaborative
Ocular Melanoma Study (COMS) recognized the need for a more
rigorous quality assurance process to reduce the deviation rate
for this disease. Ophthalmologists, radiation oncologists, med-
ical physicists, and statisticians developed a process to vet both
individuals and institutions and credential them prior to enter-
ing a patient on study. The purpose of this process was to insure
to clinical trial investigators and sponsors that the medical team
and the institution had the necessary equipment, resources, radia-
tiondose computational tools and algorithms, treatment expertise,
and understanding of both the requirements and expectations of
the protocol. This required completion of a facility questionnaire,
completion of a knowledge assessment test case, submission of
previous cases treated in a protocol format, and the viewing of
a treatment training video. Due in large part to the credential-
ing process coupled with continuous feedback to investigators,
the deviation rate on these studies was less than 5%. This was
a very important contribution as the process created a uniform
study population serving to strengthen the validation of the results
of the clinical studies (Pettersen et al., 2008). Data on a series
of protocols in Hodgkins lymphoma reviewed at QARC demon-
strate the importance of real-time intervention of both imaging
and radiation therapy treatment objects for compliance to study
radiation dose/volume trial objectives (FitzGerald et al., 2008;
FitzGerald, 2012).
In the past decade, cooperative group protocols involving the
treatment of cervical cancer permitted institutions to treat patients
with both low dose rate brachytherapy (LDR) and high dose
rate brachytherapy (HDR). Because LDR was considered stan-
dard therapy and well established, decision was made not to
perform quality assurance (QA) on patients treated with LDR.
It was presumed that LDR therapy had been performed for many
years and an assumption wasmade that treatment standards in the
community were uniform. HDR therapy was new and less familiar
to the therapy population and decision was made to establish a
strong credentialing program including HDR source calibration
and submission of two patient cases treated in a similar man-
ner to the protocol submitted for dosimetry and clinical review
including validation of the planning system calculation parame-
ters for the intended radiation dose delivery. There was no review
of LDR brachytherapy treatments prior to or during the time that
patients were entered on study. At closure of the trial, there were
no major deviations in the HDR cohort that had undergone the
rigorous credentialing process. However, as part of retrospective
review of treatment objects, there were 57 (21%) patients with
major deviations treated with LDR brachytherapy. This inﬂu-
enced trial analysis. Table 1 lists several NCI clinical trials that
had a credentialing requirement or not listed with percent major
and minor deviation. As can be seen in studies with credentialing
portfolio the deviation rate was considerably decreased in many
diverse disease-based studies with a strong credentialing program
in place.
The beneﬁt of credentialing is also illustrated by the deviation
rates in two head and neck studies that were conducted under
industry sponsorship and for which QARC coordinated the qual-
ity assurance reviews. Both studies were conducted under the same
sponsor, and both included signiﬁcant international participation.
Institutions were credentialed for the ﬁrst study by completing a
“generic”benchmark, which tested some basic treatment planning
skills but was not speciﬁc to the study in question and did not
test the investigator’s expertise in drawing treatment objects for
head and neck tumors. The major deviation rate for that study
was 24%. Because of this high deviation rate, it was decided to
use a protocol-speciﬁc benchmark to credential institutions for a
follow-up study. For the follow-up study participants were pro-
vided with an anonymized CT scan of a select patient that was
typical of the patients expected to be seen on the study. They were
asked to develop a treatment plan following protocol guidelines,
draw all target volumes of interest, and submit all of the data
that would be required for an actual protocol patient. The bench-
marks were then reviewed exactly as a plan for a protocol patient
would be reviewed, including review of target volume delineation
as well as the treatment plan itself. Themajor deviation rate for the
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follow-up study was only 8%, signiﬁcantly less than for the initial
study.
The concept of what constitutes credentialing has evolved since
ﬁrst introduced and as new radiotherapy delivery technologies,
including intensity modulated radiation therapy (IMRT), stereo-
tactic body radiation therapy (SBRT), volume modulated arc
therapy (VMAT), and proton therapy, have been included in
clinical trials (Summers et al., 2011). Credentialing should not
be confused with ongoing periodic QA activities administered by
the various QA centers. Examples of these ongoing QA activities
include protocol development, monitoring of the participating
institution’s therapy beam outputs (optically-stimulated lumines-
cent/thermoluminescent dosimeter, OSLD/TLD program), com-
pletion of generic benchmark cases, on site audits at participating
institutions and retrospective clinical and dosimetric review of
protocol patient treatments. Credentialing is the examination
and review of the institution and/or its staff as to whether they
meet certain criteria for participation in a speciﬁc clinical trial
(FitzGerald et al., 2010). Failure to meet the criteria may limit
the participation of an institution in a speciﬁc protocol. However,
the mission of the QA centers is not to restrict participation but
to assist institutions in any required remedial actions so that they
meet the criteria and can treat radiotherapy patients in a consistent
manner consistent with other participating institutions. Creden-
tialing requirementsmay include the following but, are not limited
to since they evolve with each new protocol.
1. Completion or update of a facility questionnaire
2. Demonstration of the ability to transfer radiotherapy data elec-
tronically from the institution to a central quality assurance
ofﬁce
3. Completion of a protocol knowledge assessment
4. Submission and review of previously treated patients treated in
a manner required by the protocol
5. Completion of a treatment planning protocol-speciﬁc bench-
mark case(s)
6. Completion of a modality and/or site-speciﬁc benchmark case
7. Completion of an end-to-end phantom irradiation study
8. Completion of an Image Guidance study
9. Pretreatment clinical and/or dosimetric review of an individual
protocol patient (rapid review)
The goal of credentialing is fourfold: (1) educate the institution
and its staff as to the requirements for treating the speciﬁc pro-
tocol patient, (2) verify that the institution can indeed perform
the required radiotherapy treatment accurately, (3) provide feed-
back to the institution on how to correct errors or improve their
radiotherapy treatment technique, and (4) minimize the number
of patients scored as deviations. As part of the process of clinical
trial development, decisions are made concerning the appropri-
ateness of both credentialing and data review. There are clinical
trials where data capture is the only aspect of chart review and
certain protocols (CNS leukemia, etc) do not have an assigned
credentialing or radiation therapy (RT) object review objective.
This provides the appropriate distribution of resources for the
clinical trial effort.
In 1997, the ATC was funded by the NCI to create a forum
through which the QA centers, QARC, RPC, ITC, and RTOG
QA, can work together to improve the quality of the clini-
cal trial radiotherapy data for all study groups. The ATC has
played a key role in unifying the credentialing activities and
creating reciprocity of credentialing among all study groups.
Through ATC efforts credentialing guidelines have been intro-
duced for new technologies such as recently for proton therapy
(http://rpc.mdanderson.org/RPC/home.htm). The reasoning for
each of the possible current credentialing requirements is as
follows.
FACILITY QUESTIONNAIRE
As target volume deﬁnition in protocols has become image-driven,
accelerator technology has become more complex and radiation
delivery modalities change, demonstration of the expertise of use,
appropriate comprehensive QA program, equipment/resources
necessary to deliver the radiotherapy treatment accurately is
required (Cui et al., 2012). To that end, institutions are asked to
complete or modify an existing facility questionnaire (FQ) to doc-
ument the institution’s current state of practice. In the past there
have beenmultiple FQoriginating from the study groups andqual-
ity assurance ofﬁces. Currently, there is an effort to implement a
single electronic FQ appropriate for all study groups and quality
assurance ofﬁces that is web-based. The electronic FQs sent to the
institution already completed with information from previous FQ
submissions. The institution only needs to edit their FQ to add
new information or to delete outdated information. The study
groups and quality assurance ofﬁces will also have access to this
conﬁdential information.
ELECTRONIC TRANSFER OF RADIOTHERAPY DATA
A critical component of providing QA services for radiation ther-
apy is the transfer of required data to the QA centers. Since the
mid-1990s, the ITC located in St. Louis has worked with treatment
planning vendors to encourage them to implement export of vol-
umetric dose and structures, together with the planning CT scan.
Originally the format of the digital data export was RTOG data
exchange format. This is now been largely supplanted by Digital
Imaging and Communications inMedicine (DICOM) RT. In large
measure as a result of the efforts of the ITC, nearly all commercial
planning systems as seen in Table 2, can now export volumetric
digital data in one of these two transfer formats. The QA cen-
ters have developed the ability to import and view this data which
enables comprehensive reviews to be performed byQA center staff
and/or protocol investigators. Because of the electronic nature of
these data submissions, theQA reviews can be performed remotely
by investigators as well as at a QA center. Currently, most NCI
protocols require electronic data submission and institutions are
required to demonstrate the ability to transfer data electronically
before being allowed to enter patients onto the trial. Submission
and retention of the electronic data not only aids in the review
of the radiotherapy data for QA purposes, but also archives the
information for secondary analyses to be performed after the trial
is complete.
KNOWLEDGE ASSESSMENT
The Knowledge Assessment (KA) is a QA tool that requires the
radiation oncologist and/or medical physicist to have read the
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Table 2 |Treatment planning systems with the capability to transfer data electronically to the ITC.
Treatment planning systems Exchange
format
Treatment modality
Vendor System Version1 3DCRT IMRT Seed brachy HDR brachy Protons
Accuray MultiPlan 1.5.2 D Yes
BrainLAB iPlan 4.12 D Yes Yes
Elekta CMS XiO 3.1 R Yes Yes Yes Yes
CMS XiO 4.3.1 D Yes Yes
RenderPlan 3D R Yes
PrecisePlan 2.01 D Yes Yes
Nomos Corvus R Yes3
Nucletron Helax TMS R Yes Yes
TheraPlan Plus R Yes
Oncentra MasterPlan 1.5 D Yes Yes
3.1 D Yes Yes Yes
PLATO RTS 2.62 D Yes
PLATO BPS 14.2.6 D Yes
SPOT-PRO 3.1-00 D Yes
PerMedics Odyssey 4.8.02 D Yes Yes Yes
Philips Pinnacle3 R Yes Yes
Pinnacle3 8.0h D Yes Yes
AcqPlan 4.9 R Yes
Prowess Panther 4.41 D Yes Yes Yes
Rosses Med. Strata Suite CTPlan 4.0 R Yes
RTek PIPER 2.1.2 R Yes
TomoTherapy Hi-ART 3.0 D Yes
Varian BrachyVision 6.5 D Yes
Eclipse 7.1 D Yes Yes Yes
VariSeed 7.1 D Yes
Exchange formats: D, DICOM RT objects; R, RTOG data exchange format.
1Earliest compliant version of treatment planning system.
2Please contact BrainLAB for data export procedure.
3Requires use of work-around for ATC-compliant submission.
protocol to answer the speciﬁc KA questions. These questions
cover topics such as dose prescription, treatment techniques, data
required to be submitted for each patient, allowed modalities, etc.
The KA, as a part of credentialing, improves the quality of the trial
bymeans of education andmakesmore certain that there is a com-
mon lexicon for protocol associated language. Many institutions
believe that their local radiotherapy treatment techniques are suf-
ﬁcient to meet the protocol speciﬁcations and as such do not fully
appreciate all of the protocol speciﬁcations. By completing the KA,
study groups and QA centers have the conﬁdence that each insti-
tution and/or their clinicians, dosimetrists, and medical physicists
understand what is speciﬁed by the protocol to enter an appro-
priately treated patient onto the trial instead of a patient destined
to result in a deviation. There are several tools in development to
help investigators draw treatment objects in various disease sites.
These tools will be used as benchmark tests.
SUBMISSION AND REVIEW OF A PREVIOUSLY TREATED
PATIENT, TREATED IN A MANNER REQUIRED BY A
PROTOCOL
The submission of previously treated patients in themanner speci-
ﬁed by a particular protocol enables the institution to demonstrate
to the protocol Principal Investigators (PIs) and QA centers that
they have the ability to follow the protocol correctly. They have
simulated an actual protocol patient and received feedback on how
tomake any needed treatment adjustments before even attempting
to treat the protocol patient. The key component to this credential-
ing requirement is the feedback given to the institution. This par-
ticular credentialing requirement is very similar to a rapid review
(to be detailed as the credentialing requirement number 9 listed
above) with the exception that the institution is not modifying the
actual protocol patient’s treatment, but rather a simulated protocol
patient.
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TREATMENT PLANNING PROTOCOL-SPECIFIC BENCHMARK
OR DRY RUN CASE(S)
Another approach to verifying that institutions have the abil-
ity to comply with protocol requirements is completion of
protocol-speciﬁc benchmark (aka, dry run) cases. These partic-
ular benchmark cases are intended to test the institution’s ability
tomeet one ormore protocol speciﬁc requirements such as to con-
tour target or normal tissue structures, create treatment plans that
meet prescription requirements, verify that the correct dosimetry
parameters are in the treatment planning computer in order to
accurately calculate dose, etc. Typically, a protocol-speciﬁc bench-
mark requires download of a CT scan set of a patient considered
to be representative of the protocol population. The investigator
then follows the guidelines of the protocol in delineating the tar-
get volume(s) and producing a treatment plan that complies with
the criteria of the protocol. The plan is then submitted for review,
usually electronically, and reviewed exactly as a protocol patient
would be reviewed. Completion of a protocol-speciﬁc benchmark
is similar to submission and review of a previously treated patient
except that all participants plan on the same CT scan set, resulting
in more uniform evaluation of submitted plans.
The benchmark cases are excellent QA tools to assess an insti-
tution’s ability to deﬁne target volumes per protocol since their
deﬁnition is as critical to successful protocol participation as
is treatment planning and dose delivery. Protocols are usually
speciﬁc about the volumes to be included in the clinical target
volume (CTV), which often may differ from institutional poli-
cies. By performing the benchmark case these differences can
be highlighted and participants educated as to the requirements
of the protocol through feedback from the QA center or pro-
tocol PI (Ulin et al., 2010).
MODALITY AND/OR SITE-SPECIFIC BENCHMARK CASE(S)
Treatment modalities and techniques are often common to more
than one protocol, and several modality and site-speciﬁc bench-
mark cases have been developed as credentialing tools. For many
protocols a modality and/or site-speciﬁc benchmark test may be
adequate for assessing an institution’s ability to plan a patient in
compliance with protocol requirements (Hsu et al., 2010).
Themore recently developed benchmark cases of this typemay
have electronic CT imaging datasets with target volumes embed-
ded in the CT slices. Institutions download the CT scan, plan the
treatment as prescribed in the benchmark instructions (target and
normal tissues), and submit the treatment plan, usually electron-
ically, for evaluation by a protocol PI or a QA center. There is
reciprocity amongst the QA centers and hence cooperative groups
such that an institution is required to complete a speciﬁc bench-
mark case only once. The current library of benchmark cases used
by theQA centers includes an IMRT case, stereotactic radiosurgery
(SRS) case, total body irradiation (TBI) case, brachytherapy cases,
breast cases, liver case, MRI-CT fusion case, and a proton case.
As we move toward the future with evidence-based quality
assurance, new concepts will be considered, evaluated, and imple-
mented by the QA groups. One effort initiated and completed
by members of American Association of Physicists in Medicine’s
(AAPM) task group 119 involves multi-institutional radiotherapy
and delivery data collection and comparison for quality guidance
of clinical IMRT commissioning (Ezzell et al., 2009). A set of mock
clinical cases simulating head and neck, prostate, spine cancer and
a number of other artiﬁcially developed cases designed to test the
limits of IMRT planning and delivery systems were downloaded
and planned with pre-set criteria. These plans were delivered and
veriﬁed with QA phantoms and measurement devices from the
institutions. Planning dosimetric data were collected and statis-
tically analyzed. Measurements were grouped according to the
measurement technique, and statistical analysis was reported as
well for each of the techniques. Institutions have been using these
datasets and reported results as a benchmark against which to
evaluate quantitatively their IMRT planning and delivery systems.
This approach has the advantage of simultaneous evaluation of
multiple aspects of radiation therapy patient planning that can be
performed with the institution’s equipment.
Onepossible vertical tiered approach could involve parallel data
collection initially with RPC and the dry run data submission.
Adjustment of the QA credentialing process can be made during
the study when data collected has reached statistical signiﬁcance
to suggest either continuing with the dual QA process or reducing
the processes to only one. Speciﬁc protocols can also be adjusted
to accept previous credentialing strategies providing the protocol
is not asking a new modality question or change in target volume
deﬁnition.
PHANTOM IRRADIATION STUDY
Unlike the benchmark cases and the use of a previous patient
treated in the manner speciﬁed by a protocol, which are meant to
assess the treatment planning process as it relates to the protocol,
the phantom irradiation study assesses the complete treatment
process for a speciﬁc treatment modality that might be common
to many protocols (e.g., IMRT). This thorough QA test of the
treatment process includes imaging, treatment planning, setup
for treatment, and actual delivery of the treatment. The goal of
radiotherapy QA for clinical trials is to establish consistency in
treatment delivery across a large number of participating insti-
tutions. The phantoms provide a consistent test to evaluate each
institution’s ability to deliver a speciﬁc radiotherapy treatment that
ensures that all participating institutions pass the sameQA criteria
(Ibbott et al., 2006; Kry et al., 2012). As with the benchmark cases,
reciprocity exists among the QA centers regarding the phantom
irradiation study.
Phantoms have been used to assess SRS, IMRT, SBRT, VMAT,
moving targets, and proton therapy through the use of anthro-
pomorphic head, pelvis, liver, thorax, and spine phantoms. For
a speciﬁc anatomical phantom irradiation study: all of the phan-
toms are built exactly the same, they all use the same dosimeters
(TLD and radiochromic ﬁlm), they are all evaluated using the
same established reading system, they are all analyzed using the
same analysis software and they are all judged using the same
passing criteria. Unlike relying on each institution’s own QA tests
which are highly variable among institutions, dosimetry, evalua-
tion, and passing criteria, the phantom irradiation credentialing
requirement is a QA audit that is constant from one institution to
the next helping to ensure radiotherapy treatment delivery consis-
tency for clinical trials. It provides a level of radiotherapy treatment
delivery QA consistency for multi-institutional clinical trials not
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obtained elsewhere. The speciﬁc phantom irradiation test required
for credentialing is detailed within each protocol and is requested
through the RPC (Ibbott et al., 2008).
IMAGE GUIDANCE STUDY
Credentialing for the use of image-guided radiation therapy
(IGRT) for radiation therapy protocols can verify a number of
aspects of this important validation of treatment volume. For
example, the credentialing procedure can verify physical agree-
ment or software corrected agreement between the reference
coordinate systems for the treatment device and the imaging
equipment. Also, the credentialing process can verify the accuracy
of patient linear shifts and possible rotational corrections as deter-
mined and implemented by the IGRT system. All systems have the
ability to register datasets from various imaging modalities, and
veriﬁcation of this aspect is important. Additionally, the veriﬁ-
cation can include testing of an institution’s use of the software
provided for image registration (Middleton et al., 2011).
Although it might be possible to build all of the credentialing
aspects mentioned above into a single credentialing procedure, it
is not clear that this approach is either desirable or practical. The
RTOG QA ofﬁce started a procedure for IGRT credentialing in
2009. A key feature of the overall program for IGRT credentialing
is veriﬁcation of each institution’s understanding and adherence to
instructions in protocols relating to the way image registration is
to be applied. Each study identiﬁed as an IGRT protocol includes
instructions for using IGRT. The instructions provide guidance
on considerations like: the extent of the patient’s anatomy to be
included in the registration process, the type of registration to be
employed (soft tissue, bone, other), action tolerance levels, and
the handling of rotational corrections.
PRE-TREATMENT CLINICAL AND/OR DOSIMETRIC REVIEW
OF AN INDIVIDUAL PROTOCOL PATIENT (RAPID REVIEW,
REAL-TIME REVIEW, OR TIMELY REVIEW)
One of the most useful credentialing requirements is the proto-
col patient pre-treatment clinical and/or dosimetric review by a
protocol PI or QA center. Various names are commonly used for
this type of testing: rapid, real-time, or pre-treatment review. A
related process is the timely review or on-treatment review. The
difference being that a rapid or real-time review is a review of a
protocol patient’s treatment plan before treatment begins while
the timely review is a review of the patient’s treatment plan within
the ﬁrst 3 days of treatment. With a timely review, the patient
treatment is not delayed but feedback is given to the institution
quickly enough to alter the treatment if necessary. In some situa-
tions it is not practical to modify the treatment plan. In the case
of IMRT treatment plans, the timely review process can be used
to communicate information that improves future plans submit-
ted by the same institution. For both review processes discussed
in this subsection, the key feature is the communication of treat-
ment planning and contouring information to the institution and
more speciﬁcally to the treating clinician. QARC, RTOG QA, ITC,
and the RPC are involved in facilitating or conducting these rapid
reviews (Bekelman et al., 2012). The requirement to submit patient
plan data electronically signiﬁcantly facilitates the rapid review
process. The QA centers have developed tools to permit clinicians
to review these cases from their home institutions as well as at the
QA centers. These rapid, real-time, and timely reviews provide
a consistent evaluation of the treatments ensuring comparability
across all institutions entering patients onto a speciﬁc trial, much
like the phantom irradiation study (Dharmarajan et al., 2012). An
added beneﬁt for the review techniques discussed here is the abil-
ity to identify deﬁciencies in the protocol that lead to errors in its
implementation. The early reviews can lead to amendment of the
protocols or the development of a list of frequently asked questions
aimed at decreasing protocol deviations (Chen et al., 2012).
Institutions participating in NCI funded clinical trials typi-
cally treat their patients with radiation therapy deﬁned by the
broad spectrum of reasonable practice strategies. However, for
multi-institutional clinical trials, treatments need to be compa-
rable among all participating institutions (Urie et al., 2008). Data
fromPeters et al. (2010) demonstrated the beneﬁt of protocol com-
pliant radiation therapy treatment. The study indicated that, even
if the trial is not asking a speciﬁc radiation question, the radiother-
apy component is still vital to the trial conduct and can have direct
impact on the outcome of the study. The beneﬁt of the additional
effort expended by institutions in the credentialing process helps
to ensure that the clinical trial radiotherapy treatments are accu-
rate and comparable. These QA efforts result in trial outcomes
that have not been obscured by uncertainty in the radiotherapy
treatment data.
FUTURE
All of the NCI funded cooperative clinical trial study groups and
QA centers believe that credentialing has signiﬁcantly increased
the compliance with protocol requirements. This, in turn, serves
to validate clinical trial outcome. Credentialing is highly cost efﬁ-
cient as it is far more expensive with signiﬁcant time lost if clinical
trial data is invalidated by poor quality and non-uniform patient
treatment. Poor credentialing and non-uniform treatment can
invalidate clinical trial data. Lack of guidelines in clinical trial
charter can lead to extraordinary disparities in clinical trial con-
duct (FitzGerald et al., 2008; FitzGerald, 2012; Peters et al., 2010).
The quality of the clinical trial studies has improved signiﬁcantly
and the number of deviations has decreased assuring a uniformly
treated study population. Hence credentialing will continue, but
what and how it is performed will continue to evolve. When new
technologies or treatment strategies are introduced into clinical
trials, non-uniform application of the technology is routinely seen
on quality assurance analysis during the initial phase of the trial.
Coupledwith staff changes andnew equipment purchases, creden-
tialing will remain a self-renewal process insuring both acceptance
of institutions into clinical trials and maintenance of practitioner
and institution skill set. One aspect of this evolution is the edu-
cation process that helps institutions better understand what is
required relative to treatment planning with special attention to
the segmentation of critical structures and targets. The develop-
ment of site-speciﬁc atlases is one example of the teaching tools
that can be used as a powerful educational tool. This will not
replace credentialing, however will serve to support conduct of
the trial and limit deviations on study.
Radiotherapy technology and treatment execution is likely to
become even more complex and computer-driven. As these new
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technologies are introduced into the radiation therapy commu-
nity, veriﬁcation of their appropriate use for protocol patients will
continue to be necessary. Accomplishing the objective will require
rethinking of current approaches.
Essential to credentialing efforts will be appropriateness of the
requirements and their validity for multiple groups and protocols.
Credentialing must not be overly burdensome to the participants
and must be an efﬁcient process for the QA centers while still
assuring NCI and the cooperative clinical trial groups that partic-
ipating radiotherapy facilities deliver comparable radiation doses
per protocol speciﬁcations.
Dosimetric credentialing for a particular modality or technol-
ogy will be an effort by the institution that will validate it for
all cooperative groups. Similar to the phantom studies currently
required by many protocols, successfully completing a credential-
ing process will allow participation inmultiple studies. A universal
database, accessible to the institutions as well as to the QA centers,
will be used to track and record all credentialing statuses. Issues
to be addressed include (1) what triggers a requirement for cre-
dentialing and (2) should there be sunset clauses that would at
least require the QA centers to evaluate the appropriateness of the
exercise after a deﬁned period of time.
Target volume and normal tissue credentialing may need to
be disease site-speciﬁc. Current approaches to this issue include
distribution of a protocol appropriate CT dataset, review of an
institution’s treatment of a prior patient who would have been
protocol appropriate, and pre-treatment review of the actual pro-
tocol patient. The ﬁrst approach provides a consistent dataset for
evaluation and education, while the other two provide data on
speciﬁc institutions’ patients. A consensus among the QA centers
will need to be achieved so that at the very least reciprocity among
the groups and protocols for similar disease sites can be achieved.
Atlases and web-based educational tools will aid in this process.
A tiered approach to credentialing for speciﬁc protocols may
be implemented. Protocols with quality of life endpoints may
require less rigorous credentialing relative to protocols testing
advanced technology therapy. Protocols may be possibly divided
into four categories based on the speciﬁc protocol question and
the radiotherapy modalities permitted: (1) radiotherapy as adju-
vant care, (2) standard (which will need to be deﬁned) external
beam radiotherapy delivery, (3) external beam radiotherapy and
brachytherapy or brachytherapy alone, and (4) new radiother-
apy delivery modality or radiation dose calculation technique.
Depending on the tier, the rigor and format of the credentialing
may be adjusted.
The dosimetric aspects of credentialing are primarily insti-
tutional; the target volume aspects of credentialing are pri-
marily individual (clinicians). These considerations raise sev-
eral questions. Should credentialing be separated into the two
aspects? Should clinicians be credentialed individually?Would the
credentialing move with them if they move to another institution?
How the QA centers handle the separation of the dosimetric and
clinical aspects will need to be resolved.
Imaging is a critical component of many modern protocols.
Various diagnostic studies, including CT, MRI, and PET, taken at
various times in the patient’s overall treatmentmay be essential for
protocol eligibility, target volume deﬁnition, and protocol strata as
radiotherapy clinical trials embrace the concept of adaptive radia-
tion therapy (ART). The quality of these studies must be adequate
to answer the protocol questions with minimal uncertainty. QA
centers will need to develop credentialing techniques for imag-
ing quality commensurate with imaging objectives of IROC. It is
anticipated credentialing may be performed by an imaging group
and that it would apply to all protocols and groups similar to that
proposed for a radiotherapy group. Often the images used to gen-
erate the targets for radiation therapy treatment volumes can be
used to target annotation for patient response on the same study.
Integrated imaging and radiation therapy treatment informatics
platforms can facilitate these interactions moving forward.
International participation in clinical trials is a high priority of
theNCI. But credentialing for participation creates a series of chal-
lenges since radiation therapy practice varies substantially around
the world. Regulations vary among countries and conventions and
procedures vary among countries andnon-US clinical trial groups.
Even something seemingly simple, such as the required frequency
of an external radiation dosimetric audit, may cause signiﬁcant
delay in international participation. The new QA center(s) will
need to be mindful of these variations and work with other global
QAofﬁces in an attempt to harmonizeQA efforts for these interna-
tional trials while maintaining consistency in clinical trial patient
treatments. The quality assurance centers have considerable expe-
rience in international collaboration in both group and industry
sponsored clinical trials, therefore building upon this experience
will be important moving forward as international participation
becomes imbedded in the dailywork scope of the quality assurance
centers (Trimble et al., 2009).
Going forward with the new clinical trial study group and QA
center structure, credentialing must be efﬁcient and effective. The
goal remains to minimize deviations so that trials are completed
with the most consistent and accurate data with the maximum
number of evaluable patients in order to validate clinical trial out-
come. Credentialing helps to ensure that institutions participating
in multi-institutional cooperative clinical trials are meeting pro-
tocol speciﬁcations in a comparable manner such that deviations
are kept low and the maximum amount of patient data is available
for analysis.
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